Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lifileucel - Iovance Biotherapeutics

Drug Profile

Lifileucel - Iovance Biotherapeutics

Alternative Names: AMTAGVI; Autologous TILs - Iovance Biotherapeutics; Contego™ - Iovance Biotherapeutics; LN-144; Tumour infiltrating lymphocytes - Iovance Biotherapeutics

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genesis Biopharma
  • Developer Iovance Biotherapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Malignant melanoma
  • Phase I Uveal melanoma

Most Recent Events

  • 11 Mar 2024 Iovance Biotherapeutic plans to initiate a Clinical trial for Endometrial cancer
  • 28 Feb 2024 Iovance Biotherapeutics announces intention for Regulatory submission for Malignant melanoma in Australia and other countries in 2025
  • 16 Feb 2024 Registered for Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) - First global approval
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top